Hormone therapy for sexual function in perimenopausal and postmenopausal women

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Nastri, Carolina O ^a   Lara, Lucia A ^a   Ferriani, Rui A ^a   Rosa e Silva, Ana Carolina J S ^a   Figueiredo, Jaqueline B P ^a   Martins, Wellington P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; ESTROGEN; GESTAGEN; RALOXIFENE; TIBOLONE; INDOLE DERIVATIVE; PREGNANE DERIVATIVE; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CLIMACTERIUM; DYSPAREUNIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO; ORGASM; PLEASURE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEXUAL AROUSAL; SEXUAL FUNCTION; SEXUAL SATISFACTION; SYSTEMATIC REVIEW; DRUG COMBINATION; FEMALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NORPREGNENES; PERIMENOPAUSE; POSTMENOPAUSE; PROGESTERONE; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 84887985356     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009672.pub2     Document Type: Review

References (170)

1. Czarnecka D, Klocek M, Betkowska-Korpała B, Jankowski P, Olszanecka A, Kawecka-Jaszcz K. Influence of hormone replacement therapy on the quality of life in postmenopausal women with hypertension [Wptyw hormonalnej terapii zastepczej na jakosé zycia kobiet z pierwotnym nadcisnieniem tetniczym w okresie pomenopauzalnym]. Przegl Lek 2000;57(7-8):397-401. [PUBMED: 11109313]
2. Dayal M, Sammel MD, Zhao J, Hummel AC, Vandenbourne K, Barnhart KT. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health 2005;14(5):391-400. [PUBMED: 15989411]
3. Hemminki E, Veerus P, Pisarev H, Hovi SL, Topo P, Karro H. The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial. BMC Women's Health 2009;9:16. [PUBMED: 19505307]
4. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 2006;55(2):162-73. [PUBMED: 16504428]
5. Hemminki E, Veerus P, Pisarev H, Hovi SL, Topo P, Karro H. The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial. BMC Women's Health 2009;9:16. [PUBMED: 19505307]
6. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial. Maturitas 2006;55(2):162-73. [PUBMED: 16504428]
7. Fonseca AM, Cavalcanti AL, Bagnoli VR, Paixão JS, Penteado SRL, Cardoso EB, Baracat EC. Effects of estradiol valerate associated with cyproterone acetate on some clinical and sexuality-related aspects in postmenopausal women [Efeitos do valerato de estradiol associado ao acetato de ciproterona em alguns parâmetros clínicos e da sexualidade em mulheres na pós-menopausa]. Einstein (Sao Paulo) 2008;6(2):170-4.
8. Fonseca AM, Bagnoli VR, Penteado SR, Paixão JS, Cavalcanti AL, Pinotti JA. Monophasic estrogen-progestogen therapy and sexuality in postmenopausal women. Clinical Drug Investigation 2007;27(2):131-7. [PUBMED: 17217318]
9. Gambacciani M, Rosano G, Cappagli B, Pepe A, Vitale C, Genazzani A R. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011;14(1):18-24. [PUBMED: 20979461]
10. Gast MJ, Freedman MA, Vieweg AJ, De Melo NR, Girão MJ, Zinaman MJ. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009;16(2):247-56. [PUBMED: 19034054]
11. Haines C, Yu SL, Hiemeyer F, Schaefers M. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial. Climacteric 2009;12(5):419-26. [PUBMED: 1947948]
12. Huang A, Yaffe K, Vittinghoff E, Kuppermann M, Addis I, Hanes V, et al. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. American Journal of Obstetrics and Gynecology 2008;198(3):265e1-7. [PUBMED: 18313446]
13. Hudita D, Posea C, Ceausu I, Rusu M. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. European Review for Medical and Pharmacological Sciences 2003;7(5):117-25. [PUBMED: 15214586]
14. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousabilityin postmenopausal women. Climacteric 2001;4(1):28-41. [PUBMED: 11379375]
15. Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al.Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Research 2012;14(1):R13. [PUBMED: 22251615]
16. Giulia M, Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, et al.Quality of life after breast cancer: Data from the liberate trial. Climateric 2011;14:64.
17. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al.Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncology 2009;10(2):135-46. [PUBMED: 19167925]
18. Sismondi P, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, et al.Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. Maturitas 2011;70(4):365-72. [PUBMED: 22030384]
19. Maki PM, Gast MJ, Vieweg AJ, Burriss SW, Yaffe K. Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 2007;69(13):1322-30. [PUBMED: 17893293]
20. Mameri Filho J, Haidar MA, Soares Junior JM, Baracat EC. Effects of the association of estrogen and androgen in postmenopausal women [Efeitos da associação estro-androgênica em mulheres na pós-menopausa]. Revista Brasileira de Ginecologia e Obstetrícia 2005;27(3):118-24.
21. Modugno F, Ness RB, Ewing S, Cauley JA. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Obstetrics and Gynecology 2003;101(2):353-61. [PUBMED: 12576261]
22. Morais-Socorro M, Cavalcanti MA, Martins R, Neto Francisco P, Rezende A, Azevedo G, Almeida M. Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial. Gynecological Endocrinology 2012;28(6):483-7. [PUBMED: 22132809]
23. Nathorst-Böös J, Wiklund I, Mattsson LA, Sandin K, von Schoultz B. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstetricia et Gynecologica Scandinavica 1993;72(8):656-60. [PUBMED: 8259754]
24. Nielsen TF, Ravn P, Pitkin J, Christiansen C. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-yearplacebo-controlled study. Maturitas 2006;53(2):184-90. [DOI: 10.1016/j.maturitas.2005.04.003]
25. Osmanagaoglu MA, Atasaral T, Baltaci D, Bozkaya H. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climateric 2006;9(6):464-72. [DOI: 10.1080/13697130600997775]
26. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstetrics and Gynecology 2007;109(3):588-96. [DOI: 10.1097/01.AOG.0000254160.62588.41]
27. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13(2):132-40. [PUBMED: 19863455]
28. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17(2):281-9. [PUBMED: 19779382]
29. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstetrics and Gynecology 2003;102(4):823-34. [PUBMED: 14551014]
30. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstetrics and Gynecology 2000;96(3):359-65. [PUBMED: 10960626]
31. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al. Effects of conjugated equine estrogen on health-related quality of life inpostmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Archives of Internal Medicine 2005;165(17):1976-86. [PUBMED: 16186467]
32. Gass ML, Cochrane BB, Larson JC, Manson JE, Barnabei VM, Brzyski RG, et al.Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause 2011;18(11):1160-71. [PUBMED: 21983008]
33. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al.Effects of estrogen plus progestin on health-related quality of life. The New England Journal of Medicine 2003;348(19):1839-54. [PUBMED: 12642637]
34. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62. [PUBMED: 12771112]
35. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermalestradiol therapy: a double-blind placebo-controlled study. American Journal of Obstetrics and Gynecology 1993;168:824-30. [PUBMED: 8456888]
36. Vickers MR, Martin J, Meade TW, WISDOM study team. The Women's international study of long-duration oestrogen after menopause(WISDOM): a randomised controlled trial. BMC Women's Health 2007;26(7):2. [PUBMED: 17324282]
37. Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, et al.Health related quality of life after combined hormone replacement therapy:randomised controlled trial. BMJ 2008;337(a1190):1-9. [PUBMED: 18719013]
38. Yang TS, Wang HL, Chen YJ, Chang SP, Yuan CC. Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan. Journal of the Chinese Medical Association 2004;67(7):336-43. [PUBMED: 15510930]
39. Adler G, Young D, Galant R, Quinn L, Witchger MS, Maki KC. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecologic and Obstetric Investigation 2005;59(4):212-9. [PUBMED: 15753617]
40. Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiology of Aging 2006;27(1):141-9. [PUBMED: 16298249]
41. Archer DF, Pickar JH, MacAllister DC, Warren MP. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause 2012;19(6):622-9. [PUBMED: 22282101]
42. Argyroudis EM, Iatrakis G, Kourkoubas A, Georgoulias N, Kourounis G, Tsionis C, et al. Tibolone in the treatment of psychosomatic symptoms in menopause. Clinical and Experimental Obstetrics & Gynecology 1997;24(3):167-8. [PUBMED: 9478309]
43. Bachmann G, Lobo R A, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstetrics and Gynecology 2008;111(1):67-76. [PUBMED: 18165394]
44. Bachmann GA, Schaefers M, Uddin A, Utian WH. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause 2009;16(5):877-82. [PUBMED: 19458560]
45. Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010;17(3):480-6. [PUBMED: 20032798]
46. Bachmann G, Crosby U, Feldman R A, Ronkin S, Constantine GD. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial. Menopause 2011;18(5):508-14. [PUBMED: 21289525]
47. Barnabei VM, Grady D, Stovall DW, Cauley JA, Lin F, Stuenkel CA, Stefanick ML, Pickar JH. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology 2002;100(6):1209-18. [PUBMED: 12468165]
48. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM. Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 2001;38(2):137-46. [PUBMED: 11306202]
49. Blümel JE, Del Pino M, Aprikian D, Vallejo S, Sarrá S, Castelo-Branco C. Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction. Gynecological Endocrinology 2008;24(12):691-5. [Pubmed: 19172538]
50. Bruno RV. Treatment of urogenital atrophy with the local administration of oestrogens: A randomized, controlled study in climateric and postmenopausal women [Tratamento da atrofia urogenital com a administração local de estrogênios: um estudo randomizado, controlado em mulheres no climatério e na pós-menopausa]. Revista Brasileira de Medicina 2012;69(8-9):230-5.
51. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: Results from a pivotal phase III study. Menopause 2012;19(10):1130-9. [PUBMED: 22914208]
52. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women--a double-blind placebo-controlled study. Journal of Obstetrics and Gynaecology 2001;21(4):383-5. [PUBMED: 12521832]
53. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. International Urogynecology Journal and Pelvic Floor Dysfunction 1999;10(3):171-6. [PUBMED: 10430010]
54. Castelo-Branco C, Vicente JJ, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, et al.Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34(2):161-8. [PUBMED: 10714911]
55. Cayan F, Dilek U, Pata O, Dilek S. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drosperinone and tibolone on sexual function in healthy postmenopausal women. The Journal of Sexual Medicine 2008;5(1):132-8. [PUBMED: 17961145]
56. Concepcion N, Cano A, Estevez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Ferrer J. 0.005% estriol vaginal gel, a new formulation delivering an ultra-low dose of estriol per application (50 mg), is a novel treatment for postmenopausal vaginal atrophy. Climacteric 2011;14:86.
57. Nieto C, Ferrer J, Castellanos E, Casanova A, De La Calle M, Delgado JL, et al.Efficacy of an ultra low dose estriol vaginal gel in treating postmenopausal women with vaginal dryness as their most bothersome symptom. Climacteric. 2011; Vol. 14:156.
58. Dennerstein L, Burrows GD, Hyman GJ, Sharpe K. Some clinical effects of oestrogen-progestogen therapy in surgically castrated women. Maturitas 1980;2(1):19-28. [PUBMED: 7402084]
59. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004;11(1):49-56. [PUBMED: 14716182]
60. Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes V, Ensrud K. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Menopause 2006;13(1):130-8. [PUBMED: 16607109]
61. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstetrics and Gynecology 1991;78(6):991-5. [PUBMED: 1658700]
62. Duka T, Tasker R, McGowan JF. The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females. Psychopharmacology 2000;149(2):129-39. [PUBMED: 10805607]
63. Eftekhar T, Akhoondzadeh S, Ghanbari Z, Iranshahr R, Haghollahi F. Effect of vaginal estrogen on post menopausal mood & sleep disturbance/ and sexual satisfaction. Tehran University Medical Journal 2009;67(2):118-24.
64. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 1992;44(2):137-44. [PUBMED: 1587379]
65. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology 1999;180(5):1072-9. [PUBMED: 10329858]
66. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009;16(4):735-41. [PUBMED: 19252451]
67. Galhardo CL, Soares JM Jr, Simões RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clinical and Experimental Obstetrics & Gynecology 2006;33(2):85-9. [PUBMED: 16903243]
68. Gonenne J, Esfandyari T, Camilleri M, Burton DD, Stephens DA, Baxter KL, et al. Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. Neurogastroenterology and Motility 2006;18(10):911-8. [PUBMED: 16961694]
69. Gorenstein C, Rennó J Jr, Vieira Filho AH, Gianfaldoni A, Gonçalves MA, Halbe HW, et al. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. Archives of Women's Mental Health 2011;14(5):367-73. [PUBMED: 21732218]
70. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012;71(4):360-8. [PUBMED: 22285095]
71. Guan YT, Cai LL, Ding HX, Chen GD, Hu Y. Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women. Zhonghua Fu Chan Ke Za Zhi 2010;45(8):571-4. [PUBMED: 21029610]
72. Hachul H, Bittencourt LR, Andersen ML, Haidar MA, Baracat EC, Tufik S. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. International Journal of Gynaecology and Obstetrics 2008;103(3):207-12. [PUBMED: 18812241]
73. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2009;16(1):132-40. [PUBMED: 18971794]
74. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293(8):935-48. [PUBMED: 15728164]
75. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2001;135(11):939-53. [PUBMED: 11730394]
76. Hofling M, Carlstrom K, Svane G, Azavedo E, Kloosterboer H, Von Schoultz B. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density. Gynecological Endocrinology 2005;20(2):110-5. [PUBMED: 15823831]
77. Jensen J, Christiansen C. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial. Maturitas 1983;5(2):125-33. [PUBMED: 6415364]
78. Kenny AM, Kleppinger A, Wang Y, Prestwood KM. Effects of ultra-low-dose estrogen therapy on muscle and physical function in older women. Journal of the American Geriatrics Society 2005;53(11):1973-7. [PUBMED: 16274381]
79. Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 2003;6(3):248-56. [PUBMED: 14567773]
80. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Hormones and Behavior 1995;29(3):312-21. [PUBMED: 7490007]
81. Kocoska-Maras L, Zethraeus N, Rådestad AF, Ellingsen T, von Schoultz B, Johannesson M, Hirschberg AL. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and Sterility 2011;95(1):152-7. [PUBMED: 20667535]
82. Kornafel KL, March CM. Estradiol gel in the treatment of menopausal symptoms: a placebo-controlled double-blind case study of efficacy and safety. Southern Medical Journal 1992;85(3):270-3. [PUBMED: 1546351]
83. Kumru S, Yildiz F M, Godekmerdan A, Kutlu S, Yilmaz B, Gurates B. Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial. Archives of Gynecology and Obstetrics 2008;277(6):489-93. [PUBMED: 18066566]
84. Lin SQ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, et al. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric 2011;14(4):472-81. [PUBMED: 21469973]
85. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287(20):2668-76. [PUBMED: 12020302]
86. Liu JH, Reape KZ, Hait HI. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial. Obstetrics and Gynecology 2012;119(1):78-84. [PUBMED: 22183214]
87. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effectson metabolic parameters and overall safety profile. Fertility and Sterility 2009;92(3):1025-38. [PUBMED: 19635615]
88. MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Annals of the Rheumatic Diseases 1994;53(1):54-7. [PUBMED: 8311557]
89. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?. Fertility and Sterility 2000;73(2):292-9. [PUBMED: 10685532]
90. Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004;47(1):47-54.
91. Mizunuma H. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Climacteric 2011;14(5):581-9. [PUBMED: 21848497]
92. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. Journal of Clinical Endocrinology and Metabolism 2001;86(6):2757-62. [PUBMED: 11397883]
93. Nevinny-Stickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Archives of Gynecology 1983;234(1):27-31. [PUBMED: 6660926]
94. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7(5):310-7. [PUBMED: 10993030]
95. Obel EB, Munk-Jensen N, Svenstrup B, Bennett P, Micic S, Henrik-Nielsen R, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment. Maturitas 1993;16(1):13-21. [PUBMED: 8429800]
96. Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas 1995;22(2):155-61. [PUBMED: 8538485]
97. Palacios S, Castelo-Branco C, Cancelo M J, Vazquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50(2):98-104. [PUBMED: 15653006]
98. Parkinson Study Group Poetry Investigators. A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease. Parkinsonism & Related Disorders 2011;17(10):757-60. [PUBMED: 21824799]
99. Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R. The effect of short-term estrogen replacement therapy on cognition: a randomized, double-blind, cross-over trial in postmenopausal women. Obstetrics and Gynecology 1998;91(3):459-66. [PUBMED: 9491878]
100. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003;290(8):1042-8. [PUBMED: 12941676]
101. Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3(3):176-82. [PUBMED: 11910619]
102. Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L Jr, et al. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertility and Sterility 2002;78(3):469-72. [PUBMED: 12215319]
103. Ribom EL, Svensson P, van Os S, Larsson M, Naessen T. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women. Menopause 2011;18(2):194-7. [PUBMED: 20689464]
104. Rigano A, Rigano M, Cancellieri F, Pullè C. Sexually and well-being in early menopause. Effect of transdermal estradiol therapy. Panminerva Medica 2001;43(2):115-8. [PUBMED: 11449182]
105. Saletu B, Anderer P, Gruber D, Metka M, Huber J, Saletu-Zyhlarz GM. Hormone replacement therapy and vigilance: double-blind, placebo-controlled EEG-mapping studies with an estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone in menopausal syndrome patients. Maturitas 2002;43(3):165-81. [PUBMED: 12443834]
106. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes. Diabetes Care 1999;22(9):1401-7. [PUBMED: 10480500]
107. Shah S, Bell RJ, Savage G, Goldstat R, Papalia MA, Kulkarni J, et al. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause 2006;13(4):600-8. [PUBMED: 16837882]
108. Sherman AM, Shumaker SA, Kancler C, Zheng B, Reboussin DM, Legault C, et al. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. Journal of Women's Health 2003;12(4):351-62. [PUBMED: 12804342]
109. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9(3):195-207. [PUBMED: 11973443]
110. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6(2):138-46. [PUBMED: 10374221]
111. Simon J, Nachtigall L, Gut R, Lang E, Archer D F, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstetrics and Gynecology 2008;112(5):1053-60. [PUBMED: 18978105]
112. Simon JA, Reape KZ, Wininger S, Hait H. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertility and Sterility 2008;90(4):1132-8. [PUBMED: 18053998]
113. Bachmann G, Goldstein S, Lin V, Simon J, Portman D, Phelps M. Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women. Climacteric 2011;14:92.
114. Goldstein S, Bachmann G, Lin V, Simon J, Portman D, Phelps M. Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year. Climacteric 2011;14:77.
115. Portman D, Simon J, Goldstein S. Safety and efficacy of ospemifene, a selective estrogen receptor modulator, for treatement of postmenopausal women with vulvovaginal atrophy. Journal of Sexual Medicine 2012;9:165.
116. Simon JA, Lin VH, Radovich C, Bachmann GA, The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause 2012;In press. [PUBMED: 23096251]
117. Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. International Federation of Gynaecology and Obstetrics 2003;82(2):187-97. [PUBMED: 12873780]
118. Sorensen MB, Rosenfalck AM, Hojgaard L, Ottesen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obesity Research 2001;9(10):622-6. [PUBMED: 11595778]
119. Speroff L, Haney AF, Gilbert RD, Ellman H, Estradiol Acetate Investigator Group. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause 2006;13(3):442-50. [PUBMED: 16735941]
120. Stening KD, Eriksson O, Henriksson KG, Brynhildsen J, Lindh-Åstrand L, Berg G, et al. Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial. Rheumatology 2011;50(3):544-51. [PUBMED: 21078629]
121. Stevenson JC, Durand G, Kahler E, Pertynski T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010;67(3):227-32. [PUBMED: 20688442]
122. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13(6):917-25. [PUBMED: 17006377]
123. Tinelli FG, Tinelli A, Sena T. Clinical effects of hormone replacement therapy with estradiol valerate and cyproterone acetate in perimenopausal women [Effetti di un trattamento ormonale sostitutivocon estradiolo valerato e ciproterone acetatoin donne in perimenopausa]. Minerva Ginecologica 2002;54(1):67-73. [PUBMED: 11828273]
124. Tuomikoski P, Mikkola TS, Tikkanen MJ, Ylikorkala O. Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. Climacteric 2010;13(5):457-66. [PUBMED: 20442719]
125. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. The Journal of Clinical Psychiatry 2011;72(11):1552-7. [PUBMED: 21903021]
126. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertililty and Sterility 2001;75(6):1065-79. [PUBMED: 11384629]
127. Utian WH, Gass ML, Pickar JH. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause 2004;11(3):306-14. [PUBMED: 15167310]
128. Vardy MD, Lindsay R, Scotti RJ, Mikhail M, Richart RM, Nieves J, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. American Journal of Obstetrics and Gynecology 2003;189(1):81-8. [PUBMED: 12861143]
129. Veldhuis JD, Erickson D, Miles JM, Bowers CY. Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp. American Journal of Physiology Endocrinology and Metabolism 2011;300(6):E1158-65. [PUBMED: 21467302]
130. Veldhuis JD, Erickson D, Wigham J, Weist S, Miles JM, Bowers CY. Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men. The Journal of Clinical Endocrinology and Metabolism 2011;96(8):2540-7. [PUBMED: 21613353]
131. Vestergaard P, Hermann AP, Stilgren L, Tofteng CL, Sørensen OH, Eiken P, et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomised controlled study. Maturitas 2003;46(2):123-32. [PUBMED: 14559383]
132. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43(3):207-14. [PUBMED: 12443837]
133. Wolff JP, Cachelou R, Gueritee N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas 1982;4(4):239-46. [PUBMED: 7169959]
134. Woo J, Lau E, Ho SC, Cheng F, Chan C, Chan AS, et al. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause. Menopause 2003;10(4):352-61. [PUBMED: 12851519]
135. Zervoudis S, Iatrakis G, Peitsidis P, Tsikouras P, Galazios G, Liberis V, et al. Tibolone vaginal versus per os administration in the management of post-menopausal symptoms. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2009;113(2):471-7. [PUBMED: 21491823]
136. Zhou YZ, Sun LZ, Lin JF, Yang X, Zhang LJ, Qiao J, et al. Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women: a randomized, multi-center, double-blind, placebo-controlled clinical study. Zhonghua Fu Chan Ke Za Zhi 2011;46(5):345-9. [PUBMED: 21733370]
137. Zullo MA, Plotti F, Calcagno M, Palaia I, Muzii L, Manci N, et al. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial. Menopause 2005;12(4):421-7. [PUBMED: 16037757]
138. Ceausu I, Posea C, Hudit D. Tibolone treatment - Different doses and regimens. Climacteric 2011;14:117.
139. Russu MC, Mubarak N, Marin JA, Hudit D. Quality of life improvement after vaginal treatment of urogenital atrophy symptoms in postmenopause. Climateric 2011;14:181.
140. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporosis International 2012;23(1):351-63. [PUBMED: 21779819]
141. Archer DF, Lobo RA, Pan K, Chines AA, Mirkin S. Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo-and active-controlled, phase 3 trial. Menopause 2011;18:1355-6.
142. Harvey JA, Pinkerton JV, Pan K, Thompson JR, Mirkin S, Chines AA. The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women. Menopause. 2011; Vol. 18:1342.
143. Mirkin S, Archer DF, Lobo RA, Pan K, Chines AA. Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo, and active-controlled, phase 3 TRIAL. Maturitas. 2012; Vol. 71:S43-4.
144. Pinkerton JV, Pan K, Abraham L, Racketa J, Chines AA, Mirkin S. Effects of bazedoxifene/conjugated estrogens on sleep parameters and health-related quality of life in postmenopausal women. Menopause 2011;18:1346.
145. Racketa J, Pinkerton JV, Pan K, Abraham L, Chines AA, Mirkin S. Effects of bazedoxifene/conjugated estrogens on sleep parameters and health-related quality of life in postmenopausal women. Maturitas 2012;71:S59-S60.
146. American Psychiatric Association. Diagnostic and statistical manual of mental disorders - Text revision (DSM-IV-TR). 4th Edition. American Psychiatric Association, 2000.
147. Binik YM, Brotto LA, Graham CA, Segraves RT. Response of the DSM-V Sexual Dysfunctions subworkgroup to commentaries published in JSM. The Journal of Sexual Medicine 2010;7(7):2382-7. [PUBMED: 20653837]
148. Cain VS, Johannes CB, Avis NE, Mohr B, Schocken M, Skurnick J, Ory M. Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN. Journal of Sex Research 2003;40:266-76. [PUBMED: 14533021]
149. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. New Jersey: Lawrence Erlbaum Associates, 1988.
150. da Silva Lara LA, Useche B, Rosa E Silva JC, Ferriani RA, Reis RM, de Sá MF, et al. Sexuality during the climacteric period. Maturitas 2009;62(2):127-33. [PUBMED: 19186014]
151. Davis SR. Understanding female sexual function. Menopause 2009;16(3):425-6. [PUBMED: 19225425]
152. Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, et al.Short and long term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008536.pub2]
153. Gabriel Sanchez R, Sanchez Gomez LM, Carmona L, Roqué i Figuls M, Bonfill Cosp X. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002229.pub2]
154. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. American Journal of Epidemiology 2000;52(5):463-73. [PUBMED: 10981461]
155. Graziottin A, Leiblum SR. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. The Journal of Sexual Medicine 2005;2 Suppl 3:133-45. [PUBMED: 16422790]
156. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
157. Kenemans P, Speroff L, International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of theInternational Tibolone Consensus Group. Maturitas 2005;51(1):21-8. [PUBMED: 15883105]
158. Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004;11(6 Pt 2):749-65. [PUBMED: 15543027]
159. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD002978.pub2]
160. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD004143.pub4]
161. McKinley NM, Lyon LA. Menopausal attitudes, objectified body consciousness, aging anxiety, and body esteem: European American women's body experiences in midlife. Body Image 2008;5(4):375-80. [PUBMED: 18753020]
162. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19(3):257-71. [PUBMED: 22367731]
163. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63(2):138-41. [PUBMED: 19464129]
164. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). The Journal of Sexual Medicine 2009;6(3):618-9. [PUBMED: 19284468]
165. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: asystematic review to update the U.S. Preventive Services Task Force recommendations. Annals of Internal Medicine 2012;157(2):104-13. [PUBMED: 22786830]
166. Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause 2012;19(4):396-405. [PUBMED: 22076307]
167. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al, Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. The Journal of Clinical Endocrinology and Metabolism 2010;95(7 Suppl 1):1-66. [PUBMED: 20566620]
168. Stages of Reproductive Aging Workshop (STRAW). Practice Committee of the American Society for Reproductive Medicine. The menopausal transition. Fertility and Sterility 2008;90 Suppl 3:S61-5. [DOI: 10.1016/j.fertnstert.2008.08.095]
169. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD001500.pub2]
170. Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, Shifren JL. Endocrine aspects of women's sexual function. The Journal of Sexual Medicine 2010;7:561-85. [PUBMED: 20092453]